Hospital Avicenne-Neurology
Bobigny, 93000, France
NCT Number: NCT02494531
The goal of this study is to improve the diagnosis of Alzheimer's disease (AD) at two different stages (MCI and dementia) in illiterate subjects, using FDG- fluorodeoxyglucose - and florbetapir F 18 -PET imaging. This study will compare amyloid load and cerebral metabolism dysfunction in literate versus illiterate MCI and AD patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bobigny, 93000, France
Illiterate, with a higher rate in the elder and in multi-cultural population reaching, then, 20%. Most of these patients are not usually included in research studies.
Thus, AVILL would specifically focus on lower educated and illiterate patients and on use of PET imaging for early diagnosis. This study would take advantage of the collaboration with the recently launched Memento cohort.
RATIONALE:
GENERAL OBJECTIVES:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For this group, the criteria are the same as those of Memento but with specially designed neuropsychological tests for illiterate/low educated patients.
Exclusion criteria
Fluorodeoxyglucose-PET performed within 2 months
florbetapir F 18-PET performed within 2 months
Time frame: Within 2 months after inclusion
Comparison between the 2 groups (educated and non -educated) of florbetapir-18 Fluor Standardized Uptake Values (SUV) ratios (max and mean of SUVr) in MCI patients
Time frame: Within 2 months after inclusion
Comparison of florbetapir-18 Fluor SUV (Standardized Uptake Values) ratios (max and mean of SUVr) in the different groups as defined above
Time frame: Within 2 months after inclusion
Group comparison of qualitative topography of amyloid burden
Time frame: Within 2 months after inclusion
Group comparison of topography of amyloid deposit and FDG metabolism
Assistance Publique - Hôpitaux de Paris
Other
Acronym: AVILL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01582919
Alzheimer Disease, Brain Diseases
Bordeaux, France
View Trial DetailsNCT07294586
Alzheimer Disease, Brain Diseases
Colmar, Alsace, France
View Trial DetailsNCT06223438
Alzheimer Disease, Brain Diseases
Orlando, Florida, United States
View Trial DetailsNCT05754021
Alzheimer Disease, Alzheimer Disease, Early Onset
Houston, Texas, United States
View Trial Details